2,74 €
1,18 % vorgestern
L&S, 4. Juli, 22:54 Uhr
ISIN
US20451W1018
Symbol
CMPS
Berichte

Compass Pathways Plc - ADR Aktie News

Neutral
Seeking Alpha
11 Tage alt
I am moving Compass Pathways plc from Strong Buy to Hold after phase 3 COMP005 data, as results met endpoints but disappointed market expectations. Upcoming catalysts include 26-week COMP006 phase 3 data in 2H 2026 and ongoing PTSD and anorexia programs, but risks remain if future data underwhelms. The treatment resistant depression market in the 7 major markets is expected to reach $6.70 billi...
Positiv
Proactive Investors
12 Tage alt
Compass Pathways (NASDAQ:CMPS) has reported positive results from its Phase 3 trial of its synthetic formulation of psilocybin, COMP360, in patients with treatment-resistant depression (TRD), with the trial meeting its primary endpoint. A single 25 mg dose of COMP360 demonstrated a highly statistically significant and clinically meaningful reduction in depression symptom severity compared to pl...
Negativ
Invezz
12 Tage alt
Shares of Compass Pathways Plc plunged as much as 37% during pre-market trading on Monday after the company's experimental psilocybin treatment for a form of hard-to-treat depression produced results that, while technically successful, fell short of investor expectations.
Positiv
Reuters
13 Tage alt
Compass Pathways said on Monday its experimental psilocybin-based therapy helped significantly reduce symptoms of difficult-to-treat depression in a late-stage study.
Neutral
Business Wire
13 Tage alt
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the successful achievement of the primary endpoint in the ongoing Phase 3 COMP005 trial, the first of two Phase 3 trials evaluating COMP360, a synthetic, proprietary formulation of psilocybin, f...
Positiv
Proactive Investors
17 Tage alt
The Food and Drug Administration (FDA) may soon issue emergency use authorizations for psychedelic substances like psilocybin, proponents of psychedelic therapy believe, amid a shit in attitude towards psychedelic therapies under the Trump administration.   Emergency use authorizations (EUAs) are considered a more likely near-term regulatory pathway for psychedelics such as psilocybin because, ...
Neutral
Business Wire
etwa 2 Monate alt
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in a fireside chat at the 2025 RBC Capital Markets Global Healthcare Conference at 10:30 am ET on May 20th, 2025. A live audio webcast of the pr...
Neutral
Seeking Alpha
etwa 2 Monate alt
COMPASS Pathways plc (NASDAQ:CMPS ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Steve Schultz - SVP, IR Kabir Nath - CEO Teri Loxam - CFO Guy Goodwin - Chief Medical Officer Steve Levin - Chief Patient Officer Conference Call Participants Paul Matteis - Stifel Charles Duncan - Cantor Fitzgerald Athena Chin - TD Cowen Sumant Kulkarni - Canaccord Genuity Patrick T...

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen